{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:08:27Z","timestamp":1792541307477,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier","isbn-type":[{"value":"9780443193828","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.podrm.2022.11.001","type":"book-chapter","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T14:51:58Z","timestamp":1677250318000},"page":"1-37","source":"Crossref","is-referenced-by-count":10,"title":["Brimonidine"],"prefix":"10.1016","author":[{"given":"Ahmed H.","family":"Bakheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Alomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad M.","family":"Alkahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.podrm.2022.11.001_bb0010","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 3081361, Vandetanib. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Vandetanib. Accessed Jan. 29, 2022."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0015","unstructured":"Vandetanib Theoretical Analysis. Available from: https:\/\/www.medkoo.com\/products\/4783 Accessed Feb. 6, 2022."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0020","series-title":"Brimonidine","author":"Anderson","year":"2021"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0025","series-title":"The Merck Index. An Encyclopedia of Chemicals, Drugs and Biologicals","first-page":"683","year":"2006"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0030","unstructured":"https:\/\/en.wikipedia.org\/wiki\/Brimonidine. 12\/09\/2021."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0035","unstructured":"Caprelsa Assessment report by EMA. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/caprelsa-epar-public-assessment-report_en.pdf Accessed Feb. 11, 2022."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0040","series-title":"The United States Pharmacopeia (USP), USP 42 and NF 37","first-page":"578","article-title":"USP-NF brimonidine tartrate","author":"Kharidia","year":"2020"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0045","doi-asserted-by":"crossref","unstructured":"Marvin 21.19.0-13698. ChemAxon. 2021.","DOI":"10.5465\/AMBPP.2021.13698abstract"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0050","unstructured":"https:\/\/www.tradeindia.com\/products\/brimonidine-tartrate-79570-19-7-5247025.html. 12\/12\/2021"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0055","unstructured":"B.P. Bandgar, S.S. Sawant, S.M.S.J. Mukarram, A process for preparing brimonidine or salts thereof, Quickcompany, 2013 India. 27 pp. (https:\/\/www.quickcompany.in\/patents\/a-process-for-preparing-brimonidine-or-salts-thereof#documents)"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0060","series-title":"(Imidazolinylamino) Quinazolines, -Quinolines, and -Quinoxalines","author":"Danilewicz","year":"1973"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0065","series-title":"Quinoxaline and Quinazoline Derivatives","author":"Thomas","year":"1976"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0070","series-title":"(2-Imidazolin-2-ylamino) substituted-quinoxalines and-quinazolines as antihypertensive agents, June 14","first-page":"1","author":"Danielewicz","year":"1977"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0075","series-title":"Preparation of 5-Bromo-6-Aminoquinoxaline as Intermediate of Brimonidine Tartrate","author":"Chen","year":"2008"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0080","series-title":"Mild Synthesis of 6-Amino-5-Bromoquinoxaline","first-page":"54","volume":"vol. 29","author":"Zhang","year":"2009"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0085","series-title":"Bromination Synthesis of 6-Amino-5-Bromoquinoxaline","first-page":"575","volume":"vol. 26","author":"Zhang","year":"2009"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0090","series-title":"Improved Process for Preparation of 5-Bromo-6-[(2-Imidazolin-2-yl)Amino]Quinoxaline L-Tartrate as Antiglaucoma Agent","author":"Glushkov","year":"2006"},{"issue":"10","key":"10.1016\/bs.podrm.2022.11.001_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/anie.197308061","article-title":"The chemistry of dichloromethylenammonium salts (\u201cphosgenimonium salts\u201d)","volume":"12","author":"Viehe","year":"1973","journal-title":"Angew Chem Int.Ed"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0100","first-page":"14","article-title":"Novel process for the synthesis of Brimonidine and derivative","volume":"2","author":"Naik","year":"2010","journal-title":"Int. J. PharmTech Res."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0105","doi-asserted-by":"crossref","unstructured":"Attwa, M. W., Kadi, A. A., Darwish, H. W., Amer, S. M., & Al-Shakliah, N. S. (2018). Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC\u2013ESI\u2013MS\/MS. Chem. Cent. J. 12 (1), 99.","DOI":"10.1186\/s13065-018-0467-5"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0110","series-title":"Brimonidine Tartrate","first-page":"I-315","volume":"vol. 1","year":"2016"},{"issue":"16","key":"10.1016\/bs.podrm.2022.11.001_bb0115","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1002\/jssc.201500391","article-title":"Fast quantitative analysis of four tyrosine kinase inhibitors in different human plasma samples using three-way calibration-assisted liquid chromatography with diode array detection","volume":"38","author":"Xiang","year":"2015","journal-title":"J. Sep. Sci."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0120","series-title":"Human Metabolome Database (HMDB) (Brimonidine)","year":"2021"},{"issue":"3","key":"10.1016\/bs.podrm.2022.11.001_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jchromb.2008.11.009","article-title":"A rapid and sensitive LC\/MS\/MS assay for the quantitation of brimonidine in ocular fluids and tissues","volume":"877","author":"Jiang","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/elan.201200400","article-title":"An electroanalytical approach to brimonidine at boron doped diamond electrode based on its extensive voltammetric study","volume":"25","author":"Radulovic","year":"2013","journal-title":"Electroanalysis"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.electacta.2013.05.053","article-title":"An extensive study of electrochemical behavior of brimonidine and its determination at glassy carbon electrode","volume":"106","author":"Aleksi\u0107","year":"2013","journal-title":"Electrochim. Acta"},{"issue":"22","key":"10.1016\/bs.podrm.2022.11.001_bb0140","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1007\/s00216-019-01955-3","article-title":"The evaluation of short-and long-term stability studies for brimonidine in aqueous humor by DPV\/BDDE method\u2014possible application for direct assay in native samples","volume":"411","author":"Radulovi\u0107","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.microc.2018.10.042","article-title":"Chemometrics-assisted voltammetric determination of timolol maleate and brimonidine tartrate utilizing a carbon paste electrode modified with iron (III) oxide nanoparticles","volume":"145","author":"Abou Al Alamein","year":"2019","journal-title":"Microchem. J."},{"issue":"01","key":"10.1016\/bs.podrm.2022.11.001_bb0150","first-page":"251","article-title":"Multi component mode and derivative spectrophotometric methods for the simultaneous determination of timolol maleate and brimonidine tartrate","volume":"12","author":"Annapurna","year":"2018","journal-title":"Asian J. Pharm."},{"issue":"12","key":"10.1016\/bs.podrm.2022.11.001_bb0155","first-page":"725","article-title":"Derivative spectrophotometric method for estimation of brimonidine tartrate & timolol maleate in combination","volume":"7","author":"Damle","year":"2018","journal-title":"World J. Pharm. Res."},{"issue":"2","key":"10.1016\/bs.podrm.2022.11.001_bb0160","first-page":"786","article-title":"New spectrophotometric methods for the simultaneous determination of brimonidine and timolol in eye drops","volume":"10","author":"Annapurna","year":"2017","journal-title":"JCHPS"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0165","first-page":"509","article-title":"Novel analytical spectrophotometric methods for the quantification of brimonidine tartrate\u2014an \u03b1 adrenergic agonist","volume":"8","author":"Annapurna","year":"2015","journal-title":"J. Chem. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0170","first-page":"927","article-title":"Development and validation of spectrophotometric method for the determination of brimonidine in ocular implants","volume":"3","author":"de Souza","year":"2014","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0175","first-page":"1330","article-title":"Simultaneous determination of brimonidine tartrate and timolol maleate in combined pharmacetical dosage form using two different green spectrophotometric methods","volume":"3","author":"Popaniya","year":"2014","journal-title":"World J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2022.11.001_bb0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/22297928.2014.925825","article-title":"Simultaneous determination of Timolol maleate and Brimonidine tartarate in their pharmaceutical dosage form","volume":"4","author":"Rizk","year":"2014","journal-title":"Anal. Chem. Lett."},{"issue":"3","key":"10.1016\/bs.podrm.2022.11.001_bb0185","first-page":"323","article-title":"Development and validation of first order derivative UV-spectrophotometric method for determination of brimonidine tartrate in bulk and in formulation","volume":"1","author":"Jain","year":"2011","journal-title":"Asian J. Pharm. Biol. Res."},{"issue":"5","key":"10.1016\/bs.podrm.2022.11.001_bb0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jpha.2012.04.004","article-title":"A smart simple spectrophotometric method for simultaneous determination of binary mixtures","volume":"2","author":"Elzanfaly","year":"2012","journal-title":"J. Pharm. Anal."},{"issue":"1","key":"10.1016\/bs.podrm.2022.11.001_bb0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.15415\/jptrm.2019.71005","article-title":"UV-Spectrophotometry-multicomponent mode of analysis for simultaneous estimation of brinzolamide and brimonidine tartrate in bulk and ophthalmic formulation","volume":"7","author":"Jadhav","year":"2019","journal-title":"J. Pharm. Technol. Res. Manag."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/bio.2730","article-title":"Validated spectrofluorimetric and spectrophotometric methods for the determination of brimonidine tartrate in ophthalmic solutions via derivatization with NBD-Cl. Application to stability study","volume":"30","author":"Ibrahim","year":"2015","journal-title":"Luminescence"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0205","first-page":"730","article-title":"Fluorimetric quantification of brimonidine tartrate in eye drops","volume":"75","author":"Sunitha","year":"2013","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1099-0801(200008)14:5<301::AID-BMC4>3.0.CO;2-Q","article-title":"Capillary electrophoretic analysis of brimonidine in aqueous humor of the eye and blood sera and relation of its levels with intraocular pressure","volume":"14","author":"Tzovolou","year":"2000","journal-title":"Biomed. Chromatogr."},{"issue":"7","key":"10.1016\/bs.podrm.2022.11.001_bb0215","first-page":"146","article-title":"Development and validation of HPLC method for estimation of brimonidine tartrate as bulk drug and in ophthalmic formulation","volume":"7","author":"Mandan","year":"2017","journal-title":"J. Drug Deliv. Ther."},{"issue":"4","key":"10.1016\/bs.podrm.2022.11.001_bb0220","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5740\/jaoacint.16-0439","article-title":"Validated HPLC\u2013DAD method for the simultaneous determination of six selected drugs used in the treatment of glaucoma","volume":"101","author":"Baker","year":"2018","journal-title":"J. AOAC Int."},{"issue":"2","key":"10.1016\/bs.podrm.2022.11.001_bb0225","first-page":"63","article-title":"Development of RP-HPLC method for simultaneous determination of brimonidine tartrate and brinzolamide by QbD approach and its validation","volume":"11","author":"Agrawal","year":"2017","journal-title":"Eurasian J. Anal. Chem."},{"issue":"5","key":"10.1016\/bs.podrm.2022.11.001_bb0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4172\/pharmaceutical-sciences.1000162","article-title":"Validation and experimental design assisted robustness testing of RPLC method for the simultaneous analysis of brinzolamide and brimonidine Tartrate in an ophthalmic dosage form","volume":"78","author":"Christian","year":"2016","journal-title":"Indian J. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2022.11.001_bb0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jfda.2015.11.006","article-title":"Fast separation and quantification of three anti-glaucoma drugs by high-performance liquid chromatography UV detection","volume":"24","author":"Walash","year":"2016","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0240","first-page":"99","article-title":"Development and validation of high performance liquid chromatographic method for estimation of brimonidine tartrate as bulk drug and in ophthalmic formulation","volume":"12","author":"Rohan","year":"2019","journal-title":"Int. J. PharmTech Res."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0245","first-page":"306","article-title":"Method development and validation of brinzolamide and brimonidine in its bulk and ophthalmic dosage form by using RP-HPLC","volume":"6","author":"Rao","year":"2018","journal-title":"Int. J. Chem. Pharm. Sci. (Nellore, India)"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0250","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.pharma.2019.02.005","article-title":"A versatile HPLC method with an isocratic single mobile phase system for simultaneous determination of anti-glaucoma formulations containing timolol","volume":"77","author":"Ibrahim","year":"2019","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0255","first-page":"1","article-title":"Development and validation of reverse phase high performance liquid chromatographic method for estimation of brimonidine tartrate","volume":"5","author":"Laddha","year":"2016","journal-title":"Int. J. Pharma Res. Rev."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0260","first-page":"63","article-title":"Development of RP-HPLC method for simultaneous determination of brimonidine tartrate and brinzolamide by QbD approach and its validation","volume":"vol. 11","author":"Agrawal","year":"2016","journal-title":"Eurasian J. Anal. Chem."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4172\/pharmaceutical-sciences.1000162","article-title":"Validation and experimental design assisted robustness testing of rplc method for the simultaneous analysis of brinzolamide and brimonidine tartrate in an ophthalmic dosage form","volume":"78","author":"Christian","year":"2016","journal-title":"Indian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2022.11.001_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-017-0292-2","article-title":"A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI\/PHEMA drug delivery systems","volume":"11","author":"Sun","year":"2017","journal-title":"Chem. Cent. J."},{"issue":"3","key":"10.1016\/bs.podrm.2022.11.001_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2157-7064.1000230","article-title":"Development and validation of HPLC method for simultaneous estimation of brimonidine tartrate and timolol maleate in bulk and pharmaceutical dosage form","volume":"5","author":"Elshanawane","year":"2014","journal-title":"J. Chromatogr. Sep. Tech."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0280","series-title":"Annales pharmaceutiques francaises","article-title":"A versatile HPLC method with an isocratic single mobile phase system for simultaneous determination of anti-glaucoma formulations containing timolol","author":"Ibrahim","year":"2019"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0285","first-page":"150","article-title":"Analytical method development and validation of stability indicating RP-HPLC method for estimation of brinzolamide and brimonidine tartrate in an ophthalmic suspension","volume":"6","author":"Patel","year":"2019","journal-title":"IJRAR"},{"issue":"1","key":"10.1016\/bs.podrm.2022.11.001_bb0290","first-page":"46","article-title":"Design of experiment utilization to develop a simple and robust RP-UPLC method for stability indicating method of anti glaucoma ophthalmic drops","volume":"10","author":"Hafez","year":"2015","journal-title":"Eurasian J. Anal. Chem."},{"issue":"3","key":"10.1016\/bs.podrm.2022.11.001_bb0295","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1155\/2012\/647187","article-title":"Liquid chromatographic method for the analysis of brimonidine in ophthalmic formulations","volume":"9","author":"Narendra","year":"2012","journal-title":"E-J. Chem."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchromb.2016.04.012","article-title":"Simultaneous determination of timolol maleate in combination with some other anti-glaucoma drugs in rabbit aqueous humor by high performance liquid chromatography-tandem mass spectroscopy","volume":"1022","author":"Hassib","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"19","key":"10.1016\/bs.podrm.2022.11.001_bb0305","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.4155\/bio-2021-0127","article-title":"HPLC\u2013MS\/MS studies of brimonidine in rabbit aqueous humor by microdialysis","volume":"13","author":"Tang","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0310","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1007\/s00216-019-01955-3","article-title":"The evaluation of short- and long-term stability studies for brimonidine in aqueous humor by DPV\/BDDE method-possible application for direct assay in native samples","volume":"411","author":"Radulovic","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0315","series-title":"Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea","author":"Fala","year":"2021"},{"issue":"3","key":"10.1016\/bs.podrm.2022.11.001_bb0320","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002512-199812030-00005","article-title":"Brimonidine","volume":"12","author":"Adkins","year":"1998","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/bs.podrm.2022.11.001_bb0325","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JDN.0000000000000400","article-title":"Brimonidine","volume":"10","author":"Limone","year":"2018","journal-title":"J. Dermatol. Nurses Assoc."},{"key":"10.1016\/bs.podrm.2022.11.001_bb0330","author":"ALPHAGAN"},{"key":"10.1016\/bs.podrm.2022.11.001_bb0335","author":"Datapharm"}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512522000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512522000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T12:04:13Z","timestamp":1682165053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512522000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443193828"],"references-count":66,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2022.11.001","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}